Latest Healthcare Innovation News

ECS Botanics is set to launch AVANI AVA, a new medicinal cannabis range specifically designed for women’s health, aiming to capture a growing market segment with targeted formulations.

Microba Life Sciences has secured a $3.06 million R&D tax incentive refund for FY25, reinforcing its cash reserves and supporting ongoing advancements in gastrointestinal diagnostics and clinical therapeutics.

Invion Limited has expanded its global rights to the Photosoft™ technology, gaining exclusive perpetual licenses across a broad range of human and animal diseases, including cancers and infectious diseases. This milestone-based deal positions Invion to accelerate clinical development and commercialisation worldwide.

Singular Health has submitted a 510(k) premarket notification to the FDA for its enhanced 3DICOM MD Cloud platform, aiming to expand imaging capabilities and introduce a scalable, cloud-native solution for medical image management.

Recce Pharmaceuticals has reported compelling preclinical results for its inhaled anti-infective RECCE 327, demonstrating potent activity against multidrug-resistant pneumonia bacteria in mice models.

Acrux Ltd reported a remarkable surge in licensing revenue from its topical generics portfolio alongside a strategic pivot towards innovative drug delivery R&D at its 2025 Annual General Meeting.

Paradigm Biopharmaceuticals has drawn down US$5 million under its convertible note facility to fund the accelerated expansion of its global Phase 3 trial for knee osteoarthritis treatment.

Argent BioPharma has locked in an A$11 million convertible financing facility to finalize its strategic acquisition of AusCann assets and accelerate its growth plans, including a potential US stock exchange listing.

ReNerve Limited’s innovative NervAlign® Nerve Cuff has secured approval for use across the US Department of Defense and Veterans Affairs healthcare systems, marking a major milestone for the Australian medtech company.

Pathkey.AI has teamed up with Armstrong Clinical to blend AI-driven trial predictions with expert clinical strategy, aiming to boost early-phase trial success and accelerate drug development in Australia and beyond.

Control Bionics has integrated Apple’s Brain-Computer Interface protocol into its NeuroNode products, promising simpler setup and enhanced communication for users with severe impairments.

Invex Therapeutics has appointed two new non-executive directors and joint company secretaries, signaling a refreshed governance structure alongside a change of company address.